Insights from 2023 ASH Annual Meeting

 

Insights from 2023 ASH Annual Meeting
R

Clinically-Relevant Updates in ALL in Adults

By Insights from 2023 ASH Annual Meeting FEATURING Ryan Cassaday
By Insights from 2023 ASH Annual Meeting FEATURING Ryan Cassaday
243 views
February 20, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

19:28
Agios

Pyruvate Kinase Deficiency: Clinical Manifestations and Treatment Ap…

Feat. K. Yotsumoto Fertrin
Leukemia
05:08
Insights from 2023 ASH Annual Meeting

Zanubrutinib in 1L CLL: A Biomarker Analysis From the Phase 3 SEQUOI…

Feat. P. Ghia
06:13
Insights from 2023 ASH Annual Meeting

FLT3-ITD Mutated AML: PROs From the QuANTUM-First Trial of Quizartin…

Feat. E. Oliva
20:28
Insights from 2023 ASH Annual Meeting

Clinically-Relevant Updates in ALL in Adults

Feat. R. Cassaday
08:45
Insights from 2023 ASH Annual Meeting

The Best of CLL: Highlights & Key Takeaways

Feat. V. Yazbeck
22:37
Insights from 2023 ASH Annual Meeting

AML and MDS Highlights & Key Takeaways

Feat. T. Badar
21:20
Insights from 2023 ASH Annual Meeting

The Future Paradigm of HMA + Ven or Targeted Agents in AML: Sequenci…

Feat. J. Watts
06:43
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "NPM1-Mutated Myeloid Neoplasms - Outcomes W…

Feat. G. Montalban Bravo
09:01
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Asciminib + Imatinib, Nilotinib, or Dasatin…

Feat. J. Cortés
11:36
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Maintenance Rux Is Associated With Low Rate…

Feat. Z. DeFilipp
09:09
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax + Pegcrisantaspase in R/R AML - …

Feat. Y. Liu
13:15
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Bezuclastinib (CGT9486), a Novel KIT D816V …

Feat. P. Vachhani
13:07
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax With Azacitidine for Pts With Tr…

Feat. J. Garcia
06:49
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Mini-Hyper-CVD Plus Venetoclax for Older Ad…

Feat. M. Luskin
07:43
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax With Inotuzumab Ozogamicin for R…

Feat. M. Luskin
04:45
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "The Impact of Inotuzumab Ozogamicin Treatme…

Feat. I. Aldoss
05:38
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Revumenib Monotherapy in Pts With R/R KMT2A…

Feat. I. Aldoss
09:19
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "MRD-Guided Acalabrutinib, Venetoclax and Ob…

Feat. M. Fürstenau
13:31
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "COVALENT-101 Study - Covalent Menin Inhibit…

Feat. J. Lancet
01:44
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Optimizing Outcomes With Myeloablative Cond…

Feat. C. Oliai
07:55
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Treatment Patterns & Clinical Outcomes …

Feat. E. Atallah
10:08
Insights from 2023 ASH Annual Meeting

Comparison of Venetoclax Based Treatments for Patients With R/R CLL

Feat. B. Heyman
18:27
Insights from 2023 ASH Annual Meeting

FLT3-ITD Mutated AML: QuANTUM-First - Safety by Treatment Phase and …

Feat. H. Erba
18:01
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "MRD-Directed Therapy in CLL - Ready for Pri…

Feat. J. Rhodes
04:21
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Improving Long-Term Outcomes With Intensive…

Feat. C. Röllig
03:03
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Olverembatinib (HQP1351) Overcoming Ponatin…

Feat. E. Jabbour
11:00
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Oral Decitabine/Cedazuridine (ASTX727) &…

Feat. H. Atluri
11:02
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Asciminib Combined With Dasatinib and Predn…

Feat. M. Luskin
08:32
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "ALLG CML13 ASCEND-CML Study - Asciminib Tre…

Feat. D. Yeung
14:40
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "AYAs With ALL - Treatment Approaches and On…

Feat. E. Curran
14:10
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Relapse Incidence Post Unrelated alloSCT Wi…

Feat. A. Nagler
06:56
Insights from 2023 ASH Annual Meeting

Efficacy of Ibrutinib Arms Across ALPINE and ELEVATE-RR Trials in R/…

Feat. M. Shadman
07:04
Insights from 2023 ASH Annual Meeting

Impact of Ibrutinib Dose Reduction on Duration of Therapy in Patient…

Feat. M. Shadman
08:11
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "A Comparison of HMAs Combined With Ivosiden…

Feat. A. Ambinder
08:26
Insights from 2023 ASH Annual Meeting

CLL/SLL Treatment With Post-cBTKi Pirtobrutinib: 30 Months Follow-Up…

Feat. J. Woyach
06:17
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Revumenib Maintenance Therapy Following Rev…

Feat. A. Zucenka
05:12
Insights from 2023 ASH Annual Meeting

R/R CLL Treated With Fixed-Duration Pirtobrutinib Combined With Vene…

Feat. N. Shah
07:06
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Effectiveness of Venetoclax-Based Therapy A…

Feat. N. Ghosh
08:18
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Effect of Ibrutinib Flexible Dosing Strateg…

Feat. N. Ghosh
07:22
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Hypertension in Pts With CLL and Other Heme…

Feat. A. Ferrajoli
09:38
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "A Long-Term Analysis of Lenalidomide & …

Feat. C. Chen
07:18
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "A Study of Venetoclax Added to Ibrutinib to…

Feat. K. Rogers
07:32
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Understanding Differential Technologies for…

Feat. J. Cloos
10:32
Insights from 2023 ASH Annual Meeting

FLT3-ITD Mutated AML: Quizartinib, Venetoclax, & Decitabine Trip…

Feat. M. Yilmaz
07:11
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Results From a Ph1 Study of the All-Oral Re…

Feat. M. Amaya
06:57
Insights from 2023 ASH Annual Meeting

TN-CLL/SLL: Combination Treatment With Sonrotoclax (BGB-11417), a 2n…

Feat. M. Ann Anderson
05:28
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Performance of the Molecular International …

Feat. K. Chien
10:38
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax Improves Response Rates But Not …

Feat. D. Tremblay